Stoboclo (Denosumab)

More Information (API / 60mg Pre-filled Syringe)

Active Ingredients

Denosumab 60mg

Free-From

Indicators

The treatment of osteoporosis in postmenopausal women. STOBOCLO significantly reduces the risk of vertebral, non vertebral and hip fractures.
Treatment to increase bone mass in men with osteopaenia receiving androgen deprivation therapy for non-metastatic prostate cancer.
Treatment to increase bone mass in men with osteoporosis at increased risk of fracture.
Treatment to increase bone mass in women and men at increased risk of fracture due to long-term systemic glucocorticoid therapy.

Tablet Description

Clear, colourless to slightly yellow solution.

Storage Conditions

Store at 2 to 8 degrees Celsius. Do not shake. Do not freeze. Store in original container. Refrigerate. Protect from light.

Additional Information

Generic Name: Denosumab
PBS Listed: ✔
RPBS: ✘
Strength: 60mg/mL
Dosage: Injection, solution
Pack Size: 1
Schedule: S4
Shelf Life: 54 Months
Innovator: Prolia

Warnings

See Product Information and Consumer Medicine Information for this product

More Information (CH2 / 60mg Pre-filled Syringe)

Active Ingredients

Denosumab 60mg

Free-From

Indicators

The treatment of osteoporosis in postmenopausal women. STOBOCLO significantly reduces the risk of vertebral, non-vertebral and hip fractures.
Treatment to increase bone mass in men with osteopaenia receiving androgen deprivation therapy for non-metastatic prostate cancer (see section 5.1
Pharmacodynamic properties, Clinical trials).
Treatment to increase bone mass in men with osteoporosis at increased risk of fracture.
Treatment to increase bone mass in women and men at increased risk of fracture due to long-term systemic glucocorticoid therapy.